| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Restricted cash | - | 30,542 | ||
| Cash | 72,479 | 385,929 | ||
| Prepaid expenses and other current assets | 205,509 | 151,849 | ||
| Total current assets | 277,988 | 568,320 | ||
| Equipment and furnishings, less accumulated depreciation of 119,548 and 118,151, respectively | 3,465 | 3,931 | ||
| Operating lease right-of-use asset | 138,451 | 150,133 | ||
| Total assets | 419,904 | 722,384 | ||
| Accounts payable | 1,177,776 | 1,311,038 | ||
| Accrued interest-Nonrelated Party | 44,133 | 26,344 | ||
| Accrued interest-Related Party | 97,450 | 121,868 | ||
| Other accrued expenses | 2,824,285 | 2,623,420 | ||
| Notes payable | 105,860 | 54,337 | ||
| Unearned grant revenue | - | 0 | ||
| Convertible notes payable-Nonrelated Party | 1,050,000 | 650,000 | ||
| Convertible notes payable-Related Party | 1,125,000 | 1,660,000 | ||
| Operating lease liability, current portion | 47,152 | 46,232 | ||
| Total current liabilities | 6,471,656 | 6,493,239 | ||
| Notes payable, non-current portion | 23,621 | - | ||
| Operating lease liability, non-current portion | 91,637 | 103,900 | ||
| Total liabilities | 6,586,914 | 6,597,139 | ||
| Preferred stock, value-Series DConvertible Preferred Stock | 957 | 957 | ||
| Preferred stock, value-Series DOne Convertible Preferred Stock | 13,975 | 13,724 | ||
| Common stock par value 0.001 per share 1,000,000,000 shares authorized 420,279,879 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 420,280 | 420,280 | ||
| Additional paid-in capital | 255,163,053 | 254,131,964 | ||
| Accumulated other comprehensive loss | -60,327 | -60,361 | ||
| Accumulated deficit | -261,688,770 | -260,377,489 | ||
| Total provectus biopharmaceuticals, inc., stockholders deficit | -6,150,832 | -5,870,925 | ||
| Non-controlling interest in subsidiary | -16,178 | -3,830 | ||
| Total stockholders deficit | -6,167,010 | -5,874,755 | ||
| Total liabilities and stockholders deficit | 419,904 | 722,384 | ||
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)